CROI (Conference on Retroviruses and Opportunistic Infections)

In sub-Saharan Africa, herbalists and spiritual healers are working closely with researchers to help reduce HIV transmission in rural communities.

Analysis from David Alain Wohl, M.D., on new research in on HIV prevention, especially in areas that will expand and transform PrEP options.

Injectable HIV interventions are a game-changing new option for people dealing with pill fatigue, but there are implementation challenges for clinicians to consider.

David Alain Wohl, M.D., shares his thoughts on broadly neutralizing antibodies for COVID-19—and the extent to which we can hope to see similar developments in HIV.

CROI 2021 featured new research on a host of long-acting antiretrovirals in development, including less-frequent treatment injections, a weekly pill for HIV treatment, injectable PrEP, vaginal PrEP rings, and PrEP implants.

From new forms of PrEP to new data on HIV in the U.S., CROI 2021 has plenty of developments to report when it comes to preventing HIV and better understanding the drivers of the modern epidemic.

Arriving on the one-year anniversary of nationwide COVID-19 shutdowns, the 2021 Conference on Retroviruses and Opportunistic Infections won't be in person this year—but it will emphasize COVID-19 alongside important HIV prevention and treatment updates.

Pregnant people who are living with or vulnerable to HIV need to be included in clinical trials in order to close our knowledge gaps.

HVTN 702 may not have proven an effective vaccine, but scientists still learned from the research.

With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.